Michael Pourdehnad

9 Patents

• US123969952025

  Substituted 4-aminoisoindoline-1,3-dione Compounds and Second Active Agents for Combined Use

  Celgene Corporation

  0 cites
• US122631902025

  Methods and Combinations for Treatment and T Cell Modulation

  Juno Therapeutics, Inc.

  0 cites
• US121788222024

  Methods of Treating Hematological Malignancies Using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion

  Celgene Corporation

  0 cites
• US121039232024

  Methods of Treating Non-hodgkin Lymphoma Using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

  Celgene Corporation

  0 cites
• US120901472024

  Combination Therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

  Celgene Corporation

  0 cites
• US116665792023

  Methods of Treating Hematological Malignancies Using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

  Celgene Corporation

  0 cites
• US116281722023

  Methods of Treating Chronic Lymphocytic Leukemia Using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

  Celgene Corporation

  0 cites
• US115901172023

  Treatment of a Hematologic Malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

  Celgene Corporation

  0 cites
• US115835362023

  Substituted 4-aminoisoindoline-1,3-dione Compounds and Second Active Agents for Combined Use

  Celgene Corporation

  0 cites